HY-022619 / Hefei Yigong Pharmaceutical - LARVOL DELTA

In vitro and ex vivo Pharmacological Profile of HY-022619, a Novel Intravenous P2Y12 Receptor Antagonist with Rapid-onset and Sustained Antiplatelet Activity. (PubMed, Pharm Res) - "HY-022619 demonstrates rapid, potent, and sustained antiplatelet effects, supporting its potential clinical application."

Journal • Preclinical • Acute Coronary Syndrome • Cardiovascular

Phase I clinical study of safety, tolerability, and pharmacokinetics/pharmacodynamics of HY-022619 for injection in a randomized, double-blind, placebo/positive-controlled, dose-increasing single administration in healthy Chinese adult subjects (ChiCTR) - P1 | N=30 | Not yet recruiting | Sponsor: The Third Xiangya Hospital Central South University; The Third Xiangya Hospital Central South University

New P1 trial • Acute Coronary Syndrome • Cardiovascular